AKIGAI’s mission
is clear and stedfast.
“To make an EGFR-inhibitor available to as many neuropathic pain patients as possible, as quickly as possible.”
To this end, we have mapped all marketed EGFR-inhibitors and >60 development candidates that have been tested in clinical trials.
After in-silico research, experiments in rodent models, as well as years of observations in 100+ successfully treated neuropathic pain patients with 11 different pain entities, one of the EGFR-inhibitors approved for the treatment of cancer stands out.
The EGFR is one of the most studied molecules in the human body.
The Two Routes of Administration
AKIGAI's approach is twofold. We envision two paths to development of a new type of EGFR-inhibitor.
Latest news from AKIGAI
FDA grants Fast Track Designation
The development of AKI-007 has been granted a Fast Track Designation for the development of treatment against CRPS pain.
Green light from FDA - Clearance for IND and phase 2b/3 trial
AKIGAI is starting its fully financed phase 2b/3 trial in CRPS in the US in Q1_2027
AKIGAI featured in one of Europe’s largest Biotech outlet!
"AKIGAI, a Norway-based company, is hoping to change the narrative in neuropathic pain with EGFR inhibitors."
Collaborate with AKIGAI
AKIGAI is looking for partners and collaborators to help realize EGFR-inhibitors for use against neuropathic pain.
